[ET Net News Agency, 30 March 2020] UOB Kay Hian lowered its target price for WuXi
Biologics (Cayman) (02269) to HK$127.5 from HK$132.06 and maintained its "buy" rating.
The research house said WuXi's robust 2019 results are in line with its estimate. Amid
the Covid-19 pandemic, WuXi Bio saw a one-month delay in laboratory operations in 1Q, but
surging demand for R&D services is likely to boost revenue growth from 2H.
UOBKH lowered its 2020 estimates of adjusted net profit slightly from Rmb1,660m to
Rmb1,641m. It expects WuXi to generate a stronger net profit CAGR of 41.8% in 2020-22.
(KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02269 WUXI BIO
Nominal 
13.240 -0.080 (-0.601%) Research Report
30/03/2020 15:02
{I-bank focus}UOBKH cuts WuXi Biologics (02269) to HK$127.5
| Remark: | Real time quote last updated: 18/04/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |